SCHEMBL3579231

SCHEMBL3579231

O=C(O)C[C@H](NC(=O)[C@@H]1CCCCN1C(=O)c1csc(-c2ccccc2)n1)C(=O)CF

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 5/20 0.46
CASP3 P42574 4/20 0.43
CNR2 P34972 2/20 0.42
CNR1 P21554 1/20 0.42
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
CHRNA7 P36544 1/20 0.42
HTR3A P46098 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
ACKR3 P25106 1/20 0.41
KCNQ1 P51787 1/20 0.41
TRPC3 Q13507 1/20 0.40
TRPC6 Q9Y210 1/20 0.40
HPGDS O60760 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
USP30 Q70CQ3 1/20 0.39
CPT1A P50416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5491367 1.00 PIN1 (0.46) PIN1CASP3CNR2CNR1HTR3E
SCHEMBL5491375 1.00 PIN1 (0.46) PIN1CASP3CNR2CNR1HTR3E
SCHEMBL5489939 0.90 ALDH1A1 (0.47) PIN1CASP3CNR2CNR1KCNQ1
SCHEMBL5489938 0.90 ALDH1A1 (0.47) PIN1CASP3CNR2CNR1KCNQ1
SCHEMBL5496918 0.89 PIN1 (0.41) PIN1CNR2CNR1ACKR3KCNQ1
SCHEMBL5496923 0.89 PIN1 (0.41) PIN1CNR2CNR1ACKR3KCNQ1
SCHEMBL5496287 0.85 CASP3 (0.44) CASP3KCNQ1
SCHEMBL5496284 0.85 CASP3 (0.44) CASP3KCNQ1
SCHEMBL5499721 0.82 CASP3 (0.48) CASP3CNR2KCNQ1
SCHEMBL5499724 0.82 CASP3 (0.48) CASP3CNR2KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807659-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-05 US disclosed
US-20070010457-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2007-01-11 US disclosed
EP-1381602-A1 HETEROCYCLYLDICARBAMIDES AS CASPASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2004-01-21 EP disclosed
US-20030096737-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 US disclosed
WO-2002085899-A1 HETEROCYCLYLDICARBAMIDES AS CASPASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096737-A1 Caspase inhibitors and uses thereof CASP1, APAF1, CASP5 PIN1 1083/4885CASP3 9/4885CNR2 4833/4885
US-20070010457-A1 Caspase inhibitors and uses thereof CASP1, APAF1, TNF PIN1 1232/4885CASP3 8/4885CNR2 4794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.